LI

LivaNova PLCMUN LivaNova Stock Report

Last reporting period 30 Sep, 2024

Updated 11 Nov, 2024

Last price

Market cap $B

2.795

Small

Exchange

XMUN - Boerse Muenchen

LIA.MU Stock Analysis

LI

Uncovered

LivaNova PLC is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

53/100

Moderate score

Market cap $B

2.795

Dividend yield

Shares outstanding

53.565 B

LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. The firm designs, develops, manufactures and sells products and therapies to provide improvements for both the head and heart. The firm operates in three reportable segments: Cardiopulmonary, Neuromodulation and Advanced Circulatory Support. Its Cardiac Surgery Business Franchise (CS) is engaged in the development, production and sale of cardiac surgery products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and other accessories used for extracorporeal circulation, systems for autologous blood transfusion and blood washing. Its Neuromodulation Business Franchise designs develops and markets neuromodulation-based medical devices for the treatment of epilepsy and difficult-to-treat depression (DTD) and obstructive sleep apnea.

View Section: Eyestock Rating